02:21 PM EST, 03/05/2025 (MT Newswires) -- Hoth Therapeutics ( HOTH ) said Wednesday its therapeutic candidate, HT-001, showed "promising" results in a patient with metastatic breast cancer undergoing treatment with paclitaxel, trastuzumab, and pertuzumab.

The patient developed pruritic, burning red papules on the face, scalp, and upper back, a known dermatologic side effect of EGFR inhibitors, the company said.

"After just one week of applying HT-001 2% cream twice daily, the patient experienced full symptom and lesion resolution, with no recurrence of lesions in the following three weeks," it said.

The data will be presented at the upcoming American Academy of Dermatology annual meeting, Hoth said. A phase 2A trial of HT-001 in a broader patient population is being conducted.

The shares were over 7% lower in recent trading.

Price: 1.15, Change: -0.10, Percent Change: -7.66